Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis by Yuhua Jiang, Yingying Wang, Sijia Ma, Linlin Qian, Yeteng Jing, Xi Chen, Jinsheng Yang

Subjects: Get full text

New epigenome players in the regulation of PCSK9-H3K4me3 and H3K9ac alterations by statin in hypercholesterolemia by Sushmitha Duddu, Yash T. Katakia, Rituparna Chakrabarti, Pooja Sharma, Praphulla Chandra Shukla

“…Together, these findings suggest that statin induces the colocalization of H3K4me3 and H3K9ac to transcribe PCSK9 actively and that inhibiting these marks reduces PCSK9 expression and ultimately increases hepatocyte LDL uptake. …”
Get full text

Aerobic exercise alleviates statin-induced PCSK9 upregulation by increasing epoxyeicosatrienoic acid levels through the FoxO3a–Sirt6 axis by Jiahui Hu, Hao Lei, Jingyuan Chen, Leiling Liu, Yajun Gui, Kaijun Sun, Danyan Xu

Subjects: Get full text

Analysis of changes in PCSK9 and TNF-α concentrations in response to physical exercises using virtual reality in patients in the fifth stage of chronic kidney disease undergoing hemodialysis by Agnieszka Turoń-Skrzypińska, Alicja Mińko, Aleksandra Rył, Aneta Cymbaluk-Płoska, Maciej Domański, Kazimierz Ciechanowski, Iwona Rotter

“…The aim of this study was to comprehensively assess the impact of regular physical activity using virtual reality on the concentration of plasma PCSK9 protein and TNF-α in patients with stage 5 CKD treated with hemodialysis. …”
Get full text

Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China by Xing Gong, Xinting Yu, Lanlan Pu, Yang Jiao, Lin Liu, Hua Cao, Xiaofei Ji

Subjects: Get full text

Changes induced in mouse lipid metabolism by simultaneous impact of antisense oligonucleotide derivatives to <i>apoB</i>, <i>PCSK9</i>, and <i>apoCIII</i> mRNAs by S. I. Oshevski, Y. I. Ragino, E. V. Kashtanova, Y. V. Polonskaya, E. M. Stakhneva, V. P. Nikolin, N. A. Popova, N. A. Kolchanov, M. I. Voevoda

“…The following combinations of ASOs were four times injected to the mouse caudal vein: 1) ASO to apoB, 2) ASO to apoCIII, 3) ASO to apoB and ASO to PCSK9, 4) ASO to apoB, ASO to PCSK9, and ASO to apoCIII, 5) ASO to apoB (three doses), ASO to PCSK9, and ASO to apoCIII (two doses), 6) ASO to PCSK9 and (ASO to apoCIII – only in the fourth administration). …”
Get full text

Familial Hypercholesterolemia: Genetics, Symptoms, Diagnosis and Treatment - A Literature Overview by Maciej Rutkiewicz, Sabina Przygodzka, Katarzyna Gadżała, Karolina Garbino, Katarzyna Brudniak, Antoni Szuścik, Magdalena Czyczerska

Subjects: Get full text

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma by Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini

Subjects: Get full text

Causal relationship of familial hypercholesterolemia with risk of intestinal vascular disorders: A mendelian randomization study by Gang Wei, Cheng Zhang, Feng-Jie Shen, Hua-Qi Guo, Lin Liu

Subjects: Get full text

Optimal calorie restriction threshold: effect of FATmax exercise combined with different proportions of calorie restriction on hypercholesterolemia by Yuetong Wu, Li Zhang, Jing Li, Boyang Xue, Wenyuan Shang, Yingli Lu

Subjects: “…proprotein convertase subtilisin kexin type 9 (PCSK9)…”
Get full text

Association of Insomnia, Lipid Profile, and Lipid-Lowering Medications: A Narrative Review by Fang Jia, Shun-Yi Shi, Si-Fan Fei, Min Zhou, Jian-Jun Li

Subjects: “…proprotein convertase subtilisin/kexin type 9 inhibitors (pcsk9i)…”
Get full text

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases by Nicola Ferri

“…This paper summarizes the current knowledge of the basic molecular mechanism underlying the regulatory effect of LDLR expression by PCSK9 obtained from in vitro cell-cultured studies and the analysis of the crystal structure of PCSK9. …”
Get full text

Associations between lipid-lowering drugs and urate and gout outcomes: a Mendelian randomization study by Min Liu, Na Yin, Yuhang Zhu, Aili Du, Chunyuan Cai, Pengyuan Leng

“…The study’s exposures encompassed genetic variants within drug target genes (HMGCR, PCSK9, NPC1L1), each representing distinct lipid-lowering mechanisms. …”
Get full text

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a) by Frederick Berro Rivera, MD, Sung Whoy Cha, MD, Cruz Linnaeus Louisse, MD, Genquen Philip Carado, MD, John Vincent Magalong, MD, Vincent Anthony Tang, MD, Mary Grace Enriquez, MD, Martha Gulati, MD, MS, Byambaa Enkhmaa, MD, PhD, Neha Pagidipati, MD, MPH, Nishant P. Shah, MD

“…Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. …”
Get full text

Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study by Haifeng Yu, Xiaofei Zhang, Bian Wen, Shuo Hu, Bin Ni

“…CONCLUSIONS In conclusion, this study reveals inconsistent associations between genetic proxy inhibition of APOB, CETP, HMGCR, NPCIL, PCSK9 and LDLR with LRD in specific populations.…”
Get full text

The impact of a humanized bile acid composition on atherosclerosis development in hypercholesterolaemic Cyp2c70 knockout mice by Tess Yntema, Tim R. Eijgenraam, Niels J. Kloosterhuis, Rick Havinga, Mirjam H. Koster, Milaine V. Hovingh, Jan Freark de Boer, Debby P. Y. Koonen, Folkert Kuipers

“…To conclude, a human-like BA composition ameliorated PCSK9-GOF-induced hypercholesterolaemia in WD-fed mice which translated into a tendency towards smaller atherosclerotic lesions.…”
Get full text

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis by Jeff Clarke, Xiaofei Wang, Thomas Stinchcombe, Scott J Antonia, Jeffrey Crawford, Neal Ready, Konstantin H Dragnev, Lin Gu, Cameron Wood, James M Isaacs, Liliana Lyniv, Kent Weinhold, Jacob M Kaufman, Eziafa I Oduah, Betty C Tong, Dennis Wigle

“…Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. …”
Get full text

Achievement of guideline-based lipid goals among very-high-risk patients with atherosclerotic cardiovascular disease and type 2 diabetes: results in 213,380 individuals from the cv... by Satoshi Shoji, Nishant P. Shah, Peter Shrader, Laine E. Thomas, Jonathan D. Arnold, Nafeesa N. Dhalwani, Neena A. Thomas, Bethany Kalich, Elisa L. Priest, Mahanaz Syed, Cezary Wójcik, Eric D. Peterson, Ann Marie Navar

“…Overall, 76.0 % of patients were on statin, 40.5 % were on a high-intensity statin and only 5.8 % were on a statin in combination with ezetimibe or a PCSK9i monoclonal antibody. Conclusion: Almost half of all VHR patients with ASCVD and DM2 do not achieve current guideline lipid goals. …”
Get full text

Rational engineering of minimally immunogenic nucleases for gene therapy by Rumya Raghavan, Mirco J. Friedrich, Indigo King, Samuel Chau-Duy-Tam Vo, Daniel Strebinger, Blake Lash, Michael Kilian, Michael Platten, Rhiannon K. Macrae, Yifan Song, Lucas Nivon, Feng Zhang

“…SaCas9 and AsCas12a Redi variants are substantially less recognized by adaptive immune components, including reduced binding affinity to MHC molecules and attenuated generation of cytotoxic T cell responses, yet maintain wild-type levels of activity and specificity. In vivo editing of PCSK9 with SaCas9.Redi.1 is comparable in efficiency to wild-type SaCas9, but significantly reduces undesired immune responses. …”
Get full text

Low-Density Lipoprotein Cholesterol Levels in Coronary Artery Disease Patients: Opportunities for Improvement by Gary J. Martin, Meron Teklu, Edwin Mandieka, Joe Feinglass

“…At follow-up, 87.8% of patients were prescribed a statin, 9.7% were on ezetimibe, and 0.5% were on a PCSK9 inhibitor. Mean LDL-C at follow-up was 75.6 mg/dL and 45.5% of patients were on high-intensity treatment. …”
Get full text